Drug Trial Radar · NCT06414590
Neoadjuvant Tebentafusp for Uveal Melanoma
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
19
Planned (sponsor's estimate)
Start
Sep 5, 2025
Primary completion
Aug 2027
Study completion Mar 2032
Sponsor
- Lead sponsor
- Thomas Jefferson UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Immunocore Ltd
- First posted
- May 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single arm, phase II clinical trial of neoadjuvant Tebentafusp (KIMMTRAK®) in patients with locally advanced primary uveal melanoma. Patients must be HLA-A\*02:01 with large, surgically unresectable (other than complete enucleation of the eye) primary uveal melanoma. The efficacy of this treatment will be assessed with the Simon's two stage design. The choice of design is guided by a desire to stop the trial early if the actual regression rate of primary uveal melanoma is 1% or lower.
Conditions
- Locally Advanced Unresectable Uveal Melanoma
Interventions
Tebentafusp-TebnDrug
Tebentafusp will be administered as follows: 20mcg on Day 1, 30mcg on Day 8, 68 mcg on Day 15, and weekly doses of 68 mcg thereafter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Regression of primary uveal melanoma after Tebentafusp treatment in 20% of treated patients.Time frame: 3 months post-eye treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania · Recruiting
Wills Eye Hospital
Philadelphia, Pennsylvania · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.